Strange Geoff A, Maron Bradley A, Zeder Katarina, Chan Yih-Kai, Chen Alexander, Playford David, Humbert Marc, Mocumbi Ana O, Stewart Simon
Heart Research Institute, University of Sydney, Sydney, Australia.
Institute for Health Research, University of Notre Dame Australia, Fremantle, Western Australia, Australia.
J Glob Health. 2025 Mar 21;15:04098. doi: 10.7189/jogh.15.04098.
There remains a paucity of data to describe how many people worldwide are affected by pulmonary hypertension (PH), an insidious condition associated with adverse vascular remodelling, progressive heart failure, and death without proactive diagnosis and management.
We combined data on the population rate of echocardiographic investigations with tricuspid regurgitant velocity (TRV) levels observed within a clinical cohort of >500 000 people, to conservatively estimate the number of adults with mild (TRV 2.5-2.8 m/s), moderate (TRV 2.9-3.4 m/s) and severe (>3.4 m/s) PH in Australia. We then applied the estimated number of PH cases (age- and sex-specific) to World Bank population estimates for 2021.
We conservatively estimate that 16.01 (95% confidence interval (CI) = 15.31-16.71) million men and 15.53 (95% CI = 14.79-16.27) million women, representing 0.616% (95% CI = 0.589-0.643%) and 0.589% (95% CI = 0.561-0.617%) of those aged 20-79 years worldwide, are affected by mild to severe forms of PH. The highest to lowest proportion of cases occur in Southern/Western Europe ( ~ 0.84% men and ~ 0.76% women) and sub-Saharan Africa ( ~ 0.40% both sexes), respectively. In absolute terms, the greatest number of PH cases reside in Eastern ( ~ 9.0 million) and Southern ( ~ 6.5 million) Asia. PH associated with left heart disease is predominant globally, with an estimated 8.7 (0.33%) and 7.5 (0.28%) million male and female cases worldwide. However, in sub-Saharan Africa, those aged <45 years and without left heart disease account for 11.7% of all PH cases compared to <4.0% of cases in Europe/North America.
For the first-time, we provide conservative estimates of the global pattern of PH (affecting ~ 31.5 million people). These findings provide a rationale for more definitive burden-of-disease studies focusing on likely regional differences in causality and how PH might be successfully prevented/treated.
目前仍缺乏数据来描述全球有多少人受到肺动脉高压(PH)的影响,这是一种隐匿性疾病,与不良血管重塑、进行性心力衰竭以及未经积极诊断和治疗的死亡相关。
我们将超声心动图检查的人群率数据与在一个超过50万人的临床队列中观察到的三尖瓣反流速度(TRV)水平相结合,以保守估计澳大利亚轻度(TRV 2.5 - 2.8米/秒)、中度(TRV 2.9 - 3.4米/秒)和重度(>3.4米/秒)PH的成年人数。然后,我们将估计的PH病例数(按年龄和性别划分)应用于世界银行2021年的人口估计数。
我们保守估计,全球20至79岁人群中,有1601万(95%置信区间(CI)= 1531 - 1671万)男性和1553万(95% CI = 1479 - 1627万)女性受到轻度至重度PH的影响,分别占该年龄段人群的0.616%(95% CI = 0.589 - 0.643%)和0.589%(95% CI = 0.561 - 0.617%)。病例比例从高到低分别出现在南欧/西欧(男性约0.84%,女性约0.76%)和撒哈拉以南非洲(男女均约0.40%)。从绝对数量来看,PH病例数最多的地区是东亚(约900万)和南亚(约650万)。全球范围内,与左心疾病相关的PH最为常见,估计全球有870万(0.33%)男性和750万(0.28%)女性病例。然而,在撒哈拉以南非洲,年龄小于45岁且无左心疾病的人群占所有PH病例的11.7%,而在欧洲/北美这一比例小于4.0%。
我们首次提供了全球PH模式的保守估计(影响约3150万人)。这些发现为开展更具确定性的疾病负担研究提供了依据,该研究将聚焦于因果关系可能存在的地区差异以及如何成功预防/治疗PH。